(Q26992201)

Ulrich Knigge

series ordinal

2

1 reference

language of work or name

1 reference

November 2014

1 reference

1 reference

10

1 reference

PubMed

issue

14

1 reference

PubMed

page(s)

2259-77

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

PubMed

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Grading the neuroendocrine tumors of the lung: an evidence-based proposal.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Classification and nomenclature of somatostatin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Old and new peptide receptor targets in cancer: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

First clinical evidence that imaging with somatostatin receptor antagonists is feasible

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Measured human dosimetry of 68Ga-DOTATATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

PET/MRI in cancer patients: first experiences and vision from Copenhagen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Glucagon-like peptide 1-receptor scans to localize occult insulinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Glucagon-like peptide-1 receptor imaging for localization of insulinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Ga-68 DOTA-NOC Uptake in the Pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.139